Consolidated Financial Statements for the First Quarter Ended June 30, 2019 FY2020(April 1, 2019 - March 31, 2020) [UNAUDITED]

Company name: Takara Holdings Inc.

Stock exchange listings: Tokyo Stock Exchange (1st section)

Code number: 2531

URL: https://www.takara.co.jp/
Company representative: Mutsumi Kimura, President

Contact: Takuya Kakemi, General Manager of Investor Relations Dept.

TEL: (075)241-5124

Quarterly statement filing date (as planned): August 9, 2019

Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.

2. Amounts are rounded down to the nearest million yen.

1. Results for the three months ended June 30, 2019 (April 1, 2019 - June 30, 2019)

(1) Consolidated Operating results

Note: Percentages indicated changes from the same period of the previous fiscal year. Three months ended Three months ended June 30, 2018 June 30, 2019 (Millions of yen) (%) (Millions of yen) (%) Net sales 67,317 0.5 66,969 5.7 Operating income (loss) 3,548 (11.3)4.000 92.8 Ordinary income (loss) 91.6 3,912 (9.2)4,306 Net income (loss) attributable to owners of the parent 1,969 (15.7)2,337 100.9 Net income (loss) per share (Yen) 9.87 11.71 Fully diluted net income per share (Yen) Note: Comprehensive income (loss) 2,220 (1,406)

(2) Consolidated Financial position

	As of June 30, 2019	As of March 31, 2019
	(Millions of yen)	(Millions of yen)
Total assets	285,355	287,106
Net assets	178,200	179,795
Equity ratio (%)	51.2	51.6
(Reference) Equity	146,100	148,197

2. Dividends

		Dividend per share (Yen)					
	Year ended March 31, 2019	Year ending March 31, 2020	Year ending March 31, 2020 (Forecast)				
First quarter end	-	-					
Second quarter end	-		-				
Third quarter end	-		-				
Year end	18.00		20.00				
Annual	18.00		20.00				

Note: Correction of dividend forecast from the most recent dividend forecast: No

3. Forecast for the year ending March 31, 2020 (April 1, 2019 - March 31, 2020)

• • • • • • • • • • • • • • • • • • • •	Note: Percentages indicated changes from the same period of the previous fiscal year					
	Six months ending Septemb	Six months ending September 30, 2019		31,		
	zar menus enung zepteme					
	(Millions of yen)	(%)	(Millions of yen)	(%)		
Net sales	138,800	3.6	290,000	4.5		
Operating income (loss)	8,400	3.0	19,000	6.7		
Ordinary income (loss)	8,500	3.1	19,500	6.2		
Net income (loss) attributable to owners of the parent	4,600	0.5	10,700	2.8		
Net income per share (Yen)	23.04		53.60			

Note: Correction of financial forecast from the most recent financial forecast: No

4. Others

(1) Material changes in subsidiaries during this period

(Changes in specified subsidiaries that caused a change in the scope of consolidation): No

- (2) Accounting procedures specific to quarterly consolidated financial statements : No
- (3) Changes in accounting policies, accounting estimates and retrospective restatement
 - 1) Changes based on revisions of accounting standard: Yes
 - 2) Changes other than ones based on revisions of accounting standard : No
 - 3) Changes in accounting estimates : No
 - 4) Restatement: No
- (4) Number of outstanding shares (common stock)
 - 1) Number of outstanding shares at the end of each period (Treasury stocks are included)

As of June 30, 2019 : 201,699,743 As of March 31, 2019 : 201,699,743

2) Number of treasury stocks at the end of each period As of June 30, 2019 : 2,069,706

As of June 30, 2019 : 2,069,706 As of March 31, 2019 : 2,069,706

3) Average number of outstanding shares in each period

Three months ended June 30, 2019 : 199,630,037 Three months ended June 30, 2018 : 199,630,489

Contents of the attached document

1.	Qualitative Information for the Three Months Ended June 30, 2019.	2
	(1) Consolidated Financial Results	2
	(2) Consolidated Financial Position	3
	(3) Qualitative Information Regarding Consolidated Forecasts.	4
2.	Consolidated Quarterly Financial Statements and Primary Notes.	5
	(1) Consolidated Quarterly Balance Sheets.	5
	(2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Statements of Comprehensive Income (For the Three Months Ended June 30, 2019 and 2018)	7
	Consolidated Quarterly Statements of Income (For the Three Months Ended June 30, 2019 and 2018)	7
	Consolidated Quarterly Statements of Comprehensive Income (For the Three Months Ended June 30, 2019 and 2018)	8
	(3) Notes on Consolidated Quarterly Financial Statements.	9
	(Notes on Premise of Going Concern)	9
	(Notes on Material Changes in Shareholders' Equity)	9
	(Changes in Accounting Policies)	9
	(Segment Information)	ç

o Supplement for the Consolidated Quarterly Financial Statements

1. Qualitative Information for the Three Months Ended June 30, 2019

(1) Consolidated Financial Results

In the three months ended June 30, 2019, although exports and production were weak, the Japanese economy maintained a moderate recovery backed by continued improvements in the hiring and income environment. While the moderate recovery overall is expected to continue overseas, the global economic outlook remains uncertain, mainly due to such factors as the developments in trade issues, the slowdown in the Chinese economy, and the growing tension in the Middle East.

Under these economic circumstances, under the Takara Group Medium-Term Management Plan FY2020, which is the last step towards achieving its long-term Takara Group Vision 2020, the Company is aiming to build up a great number of fields in which it can beat competitors and establish a balanced business foundation able to grow revenues significantly, no matter what environmental changes occur, by further increasing the overseas sales ratio together with having a full product line-up and many products with a competitive edge, both in Japan and overseas.

As a result, in three months ended June 30, 2019, net sales were up 0.5% year on year to \(\frac{4}{2}6,317\) million. Gross profit fell 0.4% year on year to \(\frac{4}{2}6,473\) million. Operating income decreased by 11.3% year on year to \(\frac{4}{3},548\) million while ordinary income fell 9.2% year on year to \(\frac{4}{3},912\) million. Net income attributable to owners of the parent decreased by 15.7% year on year to \(\frac{4}{1},969\) million.

Results by business segment were as follows.

[Takara Shuzo]

For alcoholic beverages, in the three months ended June 30, 2019, while sales of light-alcohol refreshers remained robust, sales of shochu and sake fell, and sales of alcoholic beverages overall declined.

In the Seasonings Business, sales were level with the previous fiscal year as sales of mirin decreased while sales of other seasonings increased.

Sales of raw alcohol and other products were up mainly reflecting increased sales of industrial alcohol.

As a result, net sales for the Takara Shuzo Group fell 2.1% year on year to ¥36,009 million. Cost of sales decreased by 1.3% to ¥21,868 million. As a result, gross profit fell 3.2% year on year to ¥14,140 million. SG&A expenses were up by 1.5% year on year, to ¥13,967 million, due to increases in promotion expenses and other expenses. Accordingly, the Takara Shuzo Group recorded operating income down 79.7% year on year to ¥172 million.

[Takara Shuzo International Group]

In the three months ended June 30, 2019, sales for the Japanese Food Wholesale Business in overseas markets remained robust for Mutual Trading Co., Inc. (U.S.) and other companies. Sales of products such as sake and whiskey also increased in the Overseas Alcoholic Beverages Business. As a result, net sales for the Takara Shuzo International Group increased by 8.5% year on year to ¥19,819 million. Cost of sales increased by 12.1% year on year to ¥14,259 million. As a result, gross profit rose by 0.2% year on year to ¥5,559 million. SG&A expenses were up by 11.0% year on year to ¥4,881 million due mainly to increases in personnel expenses and other expenses. Accordingly, the Takara Shuzo International Group recorded operating income down 41.0% year on year to ¥678 million.

[Takara Bio Group]

In the three months ended June 30, 2019, net sales were down 2.2% year on year to ¥8,650 million, due to a decrease in sales of scientific instruments and the impact from the transfer of both the health food and mushroom-related business during the previous fiscal year although sales of mainstay research reagents and contract research services increased. Cost of sales fell by 21.7% year on year to ¥2,734 million, due to a lower cost rate with changes in the structure of sales for each product, and gross profit increased by 10.5% year on year to ¥5,916 million. SG&A expenses decreased by 3.8% year on year to ¥3,664 million due to a decrease in R&D expenses and other factors. Accordingly, operating income increased 45.8% year on year to ¥2,251 million.

[Other]

Net sales of the Other segment for the three months ended June 30, 2019, declined 5.6% year on year, to ¥7,682 million, as Takara Healthcare Inc. was excluded from the scope of consolidation during the previous fiscal year, accompanying the sale of shares in that company. Cost of sales declined by 2.7% year on year, to ¥6,652 million. Consequently, gross profit decreased by 21.0% year on year to ¥1,029 million. SG&A expenses fell by 35.4% year on year, to ¥512 million. As a result, operating income increased by 1.5% year on year, to ¥517 million.

Breakdown of sales results by product category

Segment	Equivalent Period of Previous Fiscal Year (From April 1, 2018, to June 30, 2018)	Period under Review (from April 1, 2019, to June 30, 2019)	YoY Comparison	
Product category	Amount (Millions of yen)	Amount (Millions of yen)		
Takara Shuzo				
Shochu	13,899	12,297	88.5	
Sake	4,153	4,111	99.0	
Light-alcohol refreshers	9,419	10,028	106.5	
Other alcoholic beverages	1,654	1,611	97.4	
Alcoholic beverages total	29,127	28,048	96.3	
Hon Mirin	3,283	3,191	97.2	
Other seasonings	2,330	2,423	104.0	
Seasonings total	5,614	5,614	100.0	
Raw alcohol, etc.	2,030	2,345	115.5	
Total	36,772	36,009	97.9	
Takara Shuzo International Group Overseas Alcoholic	_			
Beverages Business	2,384	2,493	104.6	
Japanese Food Wholesales Business in overseas markets	16,341	17,774	108.8	
Other	24	24	102.0	
Elimination of intra-Group transaction on consolidation	(478)	(473)	_	
Total	18,270	19,819	108.5	
akara Bio Group	8,847	8,650	97.8	
Reported segment total	63,890	64,479	100.9	
Other	8,137	7,682	94.4	
Segment total	72,028	72,161	100.2	
ales not allocated to usiness segments and ntersegment transactions	(5,058)	(4,844)	_	
	<u>†</u>		+	

Note: Amounts include alcohol tax but do not include consumption tax.

(2) Consolidated Financial Position

As of June 30, 2019, current assets were \(\frac{\pmathbf{\text{4}}}{173,940}\) million, a decrease of \(\frac{\pmathbf{\text{4}}}{1,071}\) million compared with that at the end of the previous fiscal year. This was primarily due to a decrease in securities of \(\frac{\pmathbf{\text{5}}}{5,834}\) million, as well as increases in cash and deposits of \(\frac{\pmathbf{\text{2}}}{2,782}\) million and merchandise and finished goods of \(\frac{\pmathbf{\text{4}}}{1,248}\) million.

Noncurrent assets were ¥111,415 million, a decrease of ¥679 million compared with that at the end of the previous fiscal year.

This was primarily due to a decrease in investments and other assets including investment securities of \$1,778 million and an increase in property, plant and equipment of \$1,430 million.

As a result, total assets were \(\frac{\pma}{2}85,355\) million, a decrease of \(\frac{\pma}{1},751\) million compared with that at the end of the previous fiscal year.

As of June 30, 2019, current liabilities were ¥62,832 million, an increase of ¥5,010 million compared with that at the end of the previous fiscal year.

This was primarily due to an increase in current portion of bonds of \$5,000 million due to transfer from noncurrent liabilities.

Noncurrent liabilities were ¥44,322 million, a decrease of ¥5,166 million compared with that at the end of the previous fiscal year.

This was primarily due to a decrease in bonds of ¥5,000 million.

As a result, total liabilities were \$107,154 million, a decrease of \$156 million compared with that at the end of the previous fiscal year. As of June 30, 2019, total net assets were \$178,200 million, a decrease of \$1,594 million compared with that at the end of the previous fiscal year.

This was primarily due to decreases of \(\xi\)1,548 million in retained earnings and \(\xi\)710 million in valuation difference on available-for-sale securities and an increase of \(\xi\)502 million in non-controlling interests.

As a result, the equity ratio totaled 51.2%, compared with 51.6% at the end of the previous fiscal year.

(3) Qualitative Information Regarding Consolidated Forecasts

The Company has not revised the consolidated forecasts for the six months ending September 30, 2019, or for the fiscal year ending March 31, 2020, that were released in the Consolidated Financial Statements for the year ended March 31, 2019, on May 14, 2019.

2. Consolidated Financial Statements and Primary Notes

(1) Consolidated Balance Sheets

Consondated Balance Sheets		(Millions of Yen)
	As of Mar. 31, 2019	As of June 30, 2019
Assets		
Current assets		
Cash and deposits	49,415	52,198
Notes and accounts receivable-trade	59,780	59,158
Securities	16,089	10,254
Merchandise and finished goods	40,600	41,848
Work in process	1,341	1,578
Raw materials and supplies	4,093	4,495
Other	4,006	4,723
Allowance for doubtful accounts	(315)	(323
Total current assets	175,011	173,940
Noncurrent assets	<u> </u>	
Property, plant and equipment	60,576	62,00°
Intangible assets		
Goodwill	12,400	12,164
Other	7,514	7,418
Total intangible assets	19,914	19,582
Investments and other assets	<u>- </u>	
Investment securities	26,143	25,063
Other	5,520	4,822
Allowance for doubtful accounts	(60)	(60
Total investments and other assets	31,603	29,825
Total noncurrent assets	112,094	111,415
Total assets	287,106	285,355

		(Millions of Yen
	As of Mar. 31, 2019	As of June 30, 2019
Liabilities		
Current liabilities		
Notes and accounts payable-trade	16,374	16,040
Short-term loans payable	9,960	9,958
Current portion of bonds	-	5,000
Accrued alcohol tax	10,224	10,724
Accrued expenses	5,809	4,783
Income taxes payable	1,879	1,238
Provision for bonuses	2,579	3,661
Provision for sales promotion expenses	1,921	2,154
Other provision	180	162
Other	8,891	9,107
Total current liabilities	57,822	62,832
Noncurrent liabilities		
Bonds payable	25,000	20,000
Long-term loans payable	5,415	5,398
Net defined benefit liability	8,757	8,770
Long-term deposits received	5,337	5,322
Other	4,977	4,830
Total noncurrent liabilities	49,489	44,322
Total liabilities	107,311	107,154
Net assets	-	
Shareholders' equity		
Capital stock	13,226	13,226
Capital surplus	2,417	2,417
Retained earnings	124,788	123,239
Treasury stock	(1,368)	(1,368)
Total shareholders' equity	139,064	137,515
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	9,814	9,104
Deferred gains or losses on hedges	114	48
Foreign currency translation adjustment	(196)	44
Remeasurements of defined benefit plans	(599)	(612)
Total accumulated other comprehensive income	9,133	8,584
Noncontrolling interests	31,597	32,100
Total net assets	179,795	178,200
Total liabilities and net assets	287,106	285,355

(2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Statements of Comprehensive Income

(Consolidated Statements of Income) (For the Three Months Ended June 30, 2019 and 2018)

	FY2019	(Millions of Yen) FY2020
	(Apr. 1, 2018 –	(Apr. 1, 2019 –
	June 30, 2018)	June 30, 2019)
Net sales	66,969	67,317
Cost of sales	40,387	40,844
Gross profit	26,582	26,473
Selling, general and administrative expenses	22,582	22,924
Operating income	4,000	3,548
Non-operating income		,
Dividends income	287	314
Other	180	315
Total non-operating income	467	630
Non-operating expenses		
Interest expenses	85	103
Foreign exchange loss	34	92
Other	42	72
Total non-operating expenses	161	260
Ordinary income	4,306	3,912
Extraordinary income	·	
Gain on sales of noncurrent assets	0	
Total extraordinary income	0	
Extraordinary loss		
Loss on sales and retirement of noncurrent assets	18	113
Loss on valuation of investment securities	-	74
Other	<u> </u>	, , , , , , , , , , , , , , , , , , ,
Total extraordinary losses	18	190
Income before income taxes	4,288	3,723
Income taxes-current	1,871	1,401
Income taxes-deferred	(496)	(295
Total income taxes	1,375	1,10:
Net income	2,912	2,617
Net income attributable to the noncontrolling interest	575	647
Net income attributable to owners of the parent	2,337	1,969

(Consolidated Quarterly Statements of Comprehensive Income) (For the Three Months Ended June 30, 2019 and 2018)

	(Millions of Yen)
FY2019	FY2020
(Apr. 1, 2018 –	(Apr. 1, 2019 –
June 30, 2018)	June 30, 2019)
2,912	2,617
(509)	(710)
226	(66)
(4,034)	389
(2)	(10)
(4,319)	(397)
(1,406)	2,220
(082)	1,421
(963)	1,421
(423)	798
(423)	190
	(Apr. 1, 2018 – June 30, 2018) 2,912 (509) 226 (4,034) (2) (4,319)

(3) Notes on Consolidated Quarterly Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Notes on Material Changes in Shareholders' Equity)

No items to report.

(Changes in Accounting Policies)

(Adoption of ASU No. 2014-09 Revenue from Contracts with Customers)

Overseas subsidiaries that apply U.S. GAAP adopted ASU No. 2014-09 Revenue from Contracts with Customers ("ASU No. 2014-09") effective from the beginning of the first quarter of the fiscal year under review. The method of recognizing the cumulative impact due to the adoption of the standard on the commencement date of adoption, which is permitted as an interim measure, was employed for the adoption of ASU No. 2014-09.

Accompanying this, revenue is recognized at the time of transfer to the customer of the promised goods or services in an amount that reflects the consideration that the entity expects to be entitled to in exchange for those goods and services.

The impact on the Consolidated Quarterly Financial Statements from the adoption of this accounting standard is immaterial.

(Adoption of IFRS 16 Leases)

Overseas subsidiaries that apply International Financial Reporting Standards (IFRS) adopted IFRS 16 Leases ("IFRS 16") effective from the beginning of the first quarter period under review. The method of recognizing the cumulative impact due to the adoption of the standard on the commencement date of adoption, which is permitted as an interim measure, was employed for the adoption of IFRS 16.

Accompanying this, as a rule, the lessee recognizes all leases as assets and liabilities on the commencement date of adoption.

The impact on the Consolidated Quarterly Financial Statements from the adoption of this accounting standard is immaterial.

(Segment Information)

- I. Equivalent Period of Previous Fiscal Year (From April 1, 2018 to June 30, 2018)
 - 1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

		Reported Segment						Amount
								recognized
								in
	Takara	Takara Shuzo	Takara		Other	Total	Adjustment	consolidate
	Shuzo	International	Bio	Subtotal	(Note: 1)	(Note: 2	(Note: 2)	d quarterly
		Group	Group					statements
								of income
								(Note: 3)
Net sales								
External customers	36,614	18,205	8,743	63,563	3,405	66,969	0	66,969
Intersegment	158	64	103	326	4,731	5,058	(5,058)	-
Total	36,772	18,270	8,847	63,890	8,137	72,028	(5,058)	66,969
Segment income (loss)	851	1,150	1,544	3,546	509	4,055	(55)	4,000

- Notes: 1. Other includes business segments that are not part of reported segments, such as the Company's real estate rental business and the transportation business of domestic Group companies among others.
 - 2. Details of adjustment amounts are as follows.
 - (1) Net sales to external customers are income from business contracting recorded at the Company.
 - (2) Segment income (loss) comprises intersegment eliminations of ¥12 million and income of the Company not allocated to business segments of ¥-67million.

- 3. Segment income (loss) has been adjusted to the operating income of consolidated quarterly statements of income.
- 2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment No items to report.

- II. Period under Review (From April 1, 2019, to June 30, 2019)
 - 1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

		Reported	Segment					Amount
								recognized in
	Takara	Takara	Takara		Other	m . 1	Adjustment	consolidated
		Shuzo	Bio	Subtotal	(Note: 1)	Total	(Note: 2)	quarterly
	Group	International Group	Group					statements of income
		··· r						(Note: 3)
Net sales								
External customers	35,874	19,766	8,650	64,290	3,023	67,313	3	67,317
Intersegment	134	53	0	188	4,659	4,847	(4,847)	-
Total	36,009	19,819	8,650	64,479	7,682	72,161	(4,844)	67,317
Segment income (loss)	172	678	2,251	3,102	517	3,619	(71)	3,548

Notes: 1. Other includes business segments that are not part of reported segments, such as the Company's real estate rental business and the transportation business of domestic Group companies among others.

- 2. Details of adjustment amounts are as follows.
 - (1) Net sales to external customers are income from business contracting recorded at the Company.
 - (2) Segment income (loss) comprises intersegment eliminations of ¥21 million and income of the Company not allocated to business segments of ¥-92 million.
- 3. Segment income (loss) has been adjusted to the operating income of consolidated quarterly statements of income.
- 2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment No items to report.



2020年3月期 第1四半期決算短信補足資料

Supplement for the Consolidated Financial Statements for the First Quarter Ended June 30, 2019

1. 宝ホールディングス(連結)

Takara Holdings Inc. -Consolidated

グループ別要約損益計算書

Consolidated Statements of Income by Business Group (Summary)

2. 宝酒造

Takara Shuzo Co.,Ltd.

要約損益計算書

Statements of Income (Summary)

3. 宝酒造インターナショナルグループ

Takara Shuzo International Group

要約損益計算書

Statements of Income (Summary)

4. タカラバイオグループ

Takara Bio Group

要約損益計算書

Statements of Income (Summary)

5. 6年間の財務サマリー(グループ別)

Six-Year Financial Summary by Business Group

6. 2020年3月期第1四半期 参考資料

Reference Data for the First Quarter Ended June 30, 2019

宝ホールディングス株式会社 TAKARA HOLDINGS INC.

IR部 Investor Relations Dept.

TEL 075(241)5124 FAX 075(241)5194 E-Mail ir@takara.co.jp

将来見通しに関する注意事項

この資料中の当社および当社グループの現在の計画、見通し、戦略、確信などのうち、歴史的事実でないものは、将来の業績に関する見通しであり、これらは現時点において入手可能な情報から得られた当社経営陣の判断に基づくものですが、重大なリスクや不確実性を含んでいる情報から得られた多くの仮定および考えに基づきなされたものであります。実際の業績は、さまざまな要素によりこれら予測とは大きく異なる結果となり得ることをご承知おきください。

実際の業績に影響を与える要素には、経済情勢、特に消費動向、為替レートの変動、法律・行政制度の変化、 競合会社の価格・製品戦略による圧力、当社の既存製品および新製品の販売力の低下、生産中断、当社の知 的所有権に対する侵害、急速な技術革新、重大な訴訟における不利な判決等がありますが、業績に影響を与 える要素はこれらに限定されるものではありません。

Forward-Looking Statements

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors.

Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

宝ホールディングス株式会社 IR部

Takara Holdings Inc. Investor Relations Dept.

TEL 075(241)5124 FAX 075(241)5194 E-Mail ir@takara.co.jp

1. 宝ホールディングス(連結):Takara Holdings Inc. -Consolidated-

グループ別要約損益計算書:Consolidated Statements of Income by Business Group (Summary)
(百万円:Millions of Yen)

	2019年3月期 第1四半期	2020年3 Apr. 1, 20		
	実績(a)	実績(b)	增減(b-a)	比(b/a)
	FY2019 (1stQ) Actual (a)	FY2020(1stQ) Actual (b)	Change (b-a)	YOY% (b/a)
宝酒造 Takara Shuzo Co., Ltd.	36,772	36,009	Δ 763	97.9%
宝酒造インターナショナルグループ Takara Shuzo International Group	18,270	19,819	1,548	108.5%
タカラバイオ グループ Takara Bio Group	8,847	8,650	Δ 196	97.8%
その他 Other	8,137	7,682	△ 455	94.4%
調整額 Adjustment	△ 5,058	Δ 4,844	214	_
売上高 Net sales	66,969	67,317	347	100.5%
売上原価 Cost of sales	40,387	40,844	457	101.1%
売上総利益 Gross profit	26,582	26,473	Δ 109	99.6%
運送費、保管料 Transportation and storage	2,452	2,513	60	102.5%
広告宣伝費 Advertising	813	606	Δ 206	74.6%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	8,426	8,676	250	103.0%
研究開発費 Research and development	1,111	1,037	Δ 74	93.3%
管理費、その他 Other, net	9,777	10,089	312	103.2%
販売費及び一般管理費 SG&A expenses	22,582	22,924	342	101.5%
宝酒造 Takara Shuzo Co., Ltd.	851	172	△ 678	20.3%
宝酒造インターナショナルグループ Takara Shuzo International Group	1,150	678	Δ 471	59.0%
タカラバイオ グループ Takara Bio Group	1,544	2,251	707	145.8%
その他 Other	509	517	7	101.5%
調整額 Adjustment	△ 55	Δ 71	Δ 15	_
営業利益(Δ:損失) Operating income(Δ:loss)	4,000	3,548	Δ 451	88.7%
受取利息·配当金 Interest and Dividends income	326	375	48	114.8%
その他営業外収益 Other, net	140	254	114	181.0%
営業外収益 Non-operating income	467	630	162	134.7%
支払利息 Interest and discounts expenses	85	101	15	118.4%
その他営業外費用 Other, net	76	165	88	216.7%
営業外費用 Non-operating expenses	161	266	104	164.8%
経常利益(Δ:損失) Ordinary income(Δ:loss)	4,306	3,912	△ 394	90.8%
特別利益 Extraordinary gain	0	1	1	_
特別損失 Extraordinary loss	18	190	172	-
税金等調整前四半期純利益(Δ:損失) Income(Δ:loss) before income taxes	4,288	3,723	△ 565	86.8%
法人税、住民税及び事業税 Current income taxes	1,375	1,105	Δ 269	80.4%
法人税等調整額 Deferred income taxes				
四半期純利益(△:損失) Net income(Δ:loss)	2,912	2,617	Δ 295	89.9%
非支配株主に帰属する四半期純利益(Δ:損失) Net income attributable to the noncontrolling interest(Δ:loss)	575	647	72	112.7%
親会社株主に帰属する四半期純利益(Δ:損失) Net income attributable to owners of the parent(Δ:loss)	2,337	1,969	△ 368	84.3%
設備投資額(有形・無形)	1,085	1,613	527	148.6%
Capital expenditures 減価償却費(有形・無形)	1,578	1,637	59	103.7%
Depreciation and Amortization のれん償却額	215	213	Δ2	98.9%
Amortization of goodwill	= 10	0		11.070

営業外収益	受取配当金314、受取損害保険金87、生命保険配当金48 など
Non-operating income	Dividends income 314, Insurance claim income87 ,Dividend income of life insurance 48 etc.
営業外費用	支払利息59、社債利息41、為替差損92 など
Non-operating expenses	Interest expenses 59, Interest on bonds 41, foreign exchange loss 92 etc.
特別利益	固定資産売却益 1
Extraordinary gain	Gain on sales of noncurrent assets 1
特別損失	固定資産除売却損113、投資有価証券評価損74 など
Extraordinary loss	Loss on sales and retirement of noncurrent assets 113, Loss on valuation of investment securities 74 etc.

2. 宝酒造:Takara Shuzo Co., Ltd.

要約損益計算書:Statements of Income (Summary)

(百万円 :Millions of Yen)

	2019年3月期 第1四半期		月期 第1四章 19 - Jun. 30, 2	
	実績(a) FY2019 (1stQ) Actual (a)	実績(b) FY2020(1stQ) Actual (b)	增減(b-a) Change (b-a)	比(b/a) YOY% (b/a)
焼酎 Shochu	13,899	12,297	△ 1,602	88.5%
清酒 Sake	4,153	4,111	△ 42	99.0%
ソフトアルコール飲料 Light-alcohol refreshers	9,419	10,028	609	106.5%
その他酒類 Other liquors	1,654	1,611	Δ 43	97.4%
本みりん	3,283	3,191	Δ 92	97.2%
Hon Mirin その他調味料	2,330	2,423	92	104.0%
Other seasonings 原料用アルコール等 Raw alcohol	2,030	2,345	314	115.5%
売上高 Net sales	36,772	36,009	△ 763	97.9%
売上原価 Cost of sales	22,161	21,868	Δ 293	98.7%
売上総利益 Gross profit	14,610	14,140	Δ 470	96.8%
運送費、保管料 Transportation and storage	1,819	1,911	91	105.0%
広告宣伝費 Advertising	704	564	△ 140	80.1%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	8,152	8,418	266	103.3%
研究開発費 Research and development	95	96	0	100.9%
管理費、その他 Other, net	2,986	2,977	△ 9	99.7%
販売費及び一般管理費 SG&A expenses	13,759	13,967	208	101.5%
営業利益(△:損失) Operating income(Δ:loss)	851	172	△ 678	20.3%
営業外収益 Non-operating income	639	202	△ 437	31.6%
営業外費用 Non-operating expenses	50	80	29	159.8%
経常利益(△:損失) Ordinary income(Δ:loss)	1,441	294	△ 1,146	20.5%
特別利益 Extraordinary gain	_	_	_	_
特別損失 Extraordinary loss	2	102	99	_
税金等調整前四半期純利益(Δ:損失) Income(Δ:loss) before income taxes	1,438	192	△ 1,246	13.4%
法人税、住民税及び事業税 Current income taxes	} 320	82	△ 238	25.6%
法人税等調整額 Deferred income taxes				
四半期純利益(Δ:損失) Net income(Δ:loss)	1,117	110	Δ 1,007	9.9%
設備投資額(有形・無形)	79	642	562	806.5%
Capital expenditures 減価償却費(有形・無形)	527	540	12	102.5%
Depreciation and Amortization	527	540	12	102.5%

3. 宝酒造インターナショナルグループ: Takara Shuzo International Group

要約損益計算書:Statements of Income (Summary)

(百万円 :Millions of Yen)

	2019年3月期 第1四半期		月期 第1四章 19 - Jun. 30, 2	
	実績(a) FY2019 (1stQ) Actual (a)	実績(b) FY2020(1stQ)	増減(b-a) Change (b-a)	比(b/a) YOY%
海外酒類事業 Overseas Alcoholic beverages business	2,384	Actual (b) 2,493		(b/a) 104.6%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	16,341	17,774	1,433	108.8%
その他	24	24	0	102.0%
Other 連結消去	△ 478	△ 473	5	_
Elimination 売上高	18,270	19,819	1,548	108.5%
Net sales 売上原価 Cost of sales	12,721	14,259	1,538	112.1%
売上総利益 Gross profit	5,549	5,559	10	100.2%
運送費、保管料 Transportation and storage	531	580	48	109.2%
広告宣伝費 Advertising	29	21	Δ7	75.5%
販売促進費 Sales promotion	129	152	23	117.9%
管理費、その他 Other, net	3,710	4,127	417	111.2%
販売費及び一般管理費 SG&A expenses	4,399	4,881	482	111.0%
海外酒類事業 Overseas Alcoholic beverages business	459	424	∆ 35	92.3%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	1,072	619	△ 452	57.8%
その他 Other	Δ 223	△ 241	∆ 18	_
調整額 Adjustment	△ 158	△ 124	34	_
営業利益(Δ:損失) Operating income(Δ:loss)	1,150	678	△ 471	59.0%
営業外収益 Non-operating income	39	66	26	167.3%
営業外費用 Non-operating expenses	28	37	8	131.8%
経常利益(△:損失) Ordinary income(Δ:loss)	1,161	707	△ 454	60.9%
特別利益 Extraordinary gain	0	0	0	_
特別損失 Extraordinary loss	4	4	0	113.0%
税金等調整前四半期純利益(Δ:損失) Income(Δ:loss) before income taxes	1,157	702	△ 454	60.7%
法人税、住民税及び事業税 Current income taxes	} 346	235	△ 111	67.9%
法人税等調整額 Deferred income taxes	J			
四半期純利益(△:損失) Net income(Δ:loss)	810	467	△ 343	57.7%
非支配株主に帰属する四半期純利益(Δ:損失) Net income attributable to the noncontrolling interest(Δ:loss)	169	21	△ 148	12.5%
親会社株主に帰属する四半期純利益(Δ:損失) Net income attributable to owners of the parent(Δ:loss)	641	446	△ 195	69.6%
設備投資額(有形・無形)	261	607	345	232.0%
Capital expenditures 減価償却費(有形・無形)	247	292	44	118.0%
Depreciation and Amortization のれん償却額	92	87	Δ4	94.9%
Amortization of goodwill		<u> </u>		

4. タカラバイオグループ: Takara Bio Group

要約損益計算書:Statements of Income (Summary)

(百万円 :Millions of Yen)

	2019年3月期 第1四半期		月期 第1四章 19 - Jun. 30, 2	
	実績(a) FY2019 (1stQ) Actual (a)	実績(b) FY2020(1stQ) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)
研究用試薬 Research reagents	5,246	5,584	337	106.4%
理化学機器 Scientific instruments	517	274	Δ 243	53.0%
受託・その他 Contracted service and other	752	888	136	118.1%
バイオ産業支援 計 Bioindustry	6,516	6,746	230	103.5%
遺伝子医療 Gene therapy	1,931	1,903	Δ 27	98.6%
その他 Other	399	_	△ 399	_
売上高 Net sales	8,847	8,650	△ 196	97.8%
売上原価 Cost of sales	3,491	2,734	△ 757	78.3%
売上総利益 Gross profit	5,355	5,916	560	110.5%
運送費、保管料 Transportation and storage	158	89	△ 68	56.8%
広告宣伝費 Advertising	16	17	1	110.8%
販売促進費 Sales promotion	164	136	Δ 27	83.2%
研究開発費 Research and development	1,014	939	Δ 75	92.6%
管理費、その他 Other, net	2,457	2,481	23	100.9%
販売費及び一般管理費 SG&A expenses	3,811	3,664	△ 146	96.2%
バイオ産業支援 計 Bioindustry	689	1,331	642	193.2%
遺伝子医療 Gene therapy	1,442	1,468	26	101.8%
その他 Other	△ 45	_	45	_
共通 Eliminations/Corporate	△ 541	△ 548	Δ7	_
営業利益(△:損失) Operating income(Δ:loss)	1,544	2,251	707	145.8%
営業外収益 Non-operating income	49	62	12	125.3%
営業外費用 Non-operating expenses	34	113	78	324.6%
経常利益(Δ:損失) Ordinary income(Δ:loss)	1,559	2,200	641	141.1%
特別利益 Extraordinary gain	_	0	0	_
特別損失 Extraordinary loss	10	9	Δ1	85.7%
税金等調整前四半期純利益(Δ:損失) Income(Δ:loss) before income taxes	1,548	2,191	643	141.6%
法人税、住民税及び事業税 Current income taxes	} 514	595	81	115.9%
法人税等調整額 Deferred income taxes				
四半期純利益(Δ:損失) Net income(Δ:loss)	1,034	1,596	561	154.3%
非支配株主に帰属する四半期純利益(Δ:損失) Net income attributable to the noncontrolling interest(Δ:loss)	2	4	2	222.4%
親会社株主に帰属する四半期純利益(Δ:損失) Net income attributable to owners of the parent(Δ:loss)	1,032	1,591	559	154.2%
設備投資額(有形·無形)	678	361	∆ 317	53.2%
Capital expenditures 減価償却費(有形・無形)	669	677	7	101.2%
Depreciation and Amortization のれん償却額 Amortization of goodwill	123	125	2	101.8%

PAGE 4/7 Takara Bio Group

5. 6年間の財務サマリー(グループ別):Six-Year Financial Summary by Business Group

宝ホールディングス (連結):Takara Holdings IncConsolidated- (译									
		2015年3月期 第1四半期	2016年3月期 第1四半期	2017年3月期 第1四半期	2018年3月期 第1四半期	2019年3月期 第1四半期	2020年3月期 第1四半期	前期 Change from	
		FY2015 (1stQ)	FY2016 (1stQ)	FY2017 (1stQ)	FY2018 (1stQ)	FY2019 (1stQ)	FY2020 (1stQ)	増減 Change	比 YOY%
売上高	Net sales	50,025	50,938	52,311	63,368	66,969	67,317	347	100.5%
売上原価	Cost of sales	31,031	31,323	31,391	38,705	40,387	40,844	457	101.1%
(売上高原価率)	(Ratio to Net sales)	62.0%	61.5%	60.0%	61.1%	60.3%	60.7%	+0.4pt	_
売上総利益	Gross profit	18,994	19,615	20,919	24,662	26,582	26,473	△ 109	99.6%
販売費及び一般管理費	SG&A expenses	17,811	18,966	19,289	22,588	22,582	22,924	342	101.5%
(売上高販管費率)	(Ratio to Net sales)	35.6%	37.2%	36.9%	35.6%	33.7%	34.1%	+0.3pt	-
営業利益(△:損失)	Operating income(Δ:loss)	1,182	649	1,630	2,074	4,000	3,548	△ 451	88.7%
(売上高営業利益率)	(Ratio to Net Sales)	2.4%	1.3%	3.1%	3.3%	6.0%	5.3%	-0.7pt	-
販売促進費、販売促進引当金繰力	Sales promotion and allowance for s.p.	8,198	8,169	8,370	8,886	8,426	8,676	250	103.0%
(売上高販促費率)	(Ratio to Net sales)	16.4%	16.0%	16.0%	14.0%	12.6%	12.9%	+0.3pt	_
研究開発費	R&D expenses	792	1,103	1,045	1,201	1,111	1,037	△ 74	93.3%
(売上高研究開発費率)	(Ratio to Net sales)	1.6%	2.2%	2.0%	1.9%	1.7%	1.5%	-0.1pt	_
設備投資額(有形・無形)	Capital expenditures	2,012	365	681	946	1,085	1,613	527	148.6%
減価償却費(有形・無形)	Depreciation and Amortization	1,012	1,216	1,245	1,522	1,578	1,637	59	103.7%
のれん償却額	Amortization of goodwill	116	133	122	194	215	213	Δ2	98.9%

									lions of Yen)
		2015年3月期 第1四半期	2016年3月期 第1四半期	2017年3月期 第1四半期	2018年3月期 第1四半期	2019年3月期 第1四半期	2020年3月期 第1四半期	前期 Change from I	
		FY2015 (1stQ)	FY2016 (1stQ)	FY2017 (1stQ)	FY2018 (1stQ)	FY2019 (1stQ)	FY2020 (1stQ)	増減 Change	比 YOY%
売上高	Net sales	_	_	34,235	36,029	36,772	36,009	△ 763	97.9%
売上原価	Cost of sales	-	_	20,797	21,665	22,161	21,868	Δ 293	98.7%
(売上高原価率)	(Ratio to Net sales)			60.7%	60.1%	60.3%	60.7%	+0.5pt	-
売上総利益	Gross profit			13,438	14,363	14,610	14,140	△ 470	96.8%
販売費及び一般管理費	SG&A expenses		期からの	13,523	14,212	13,759	13,967	208	101.5%
(売上高販管費率)	(Ratio to Net sales)	新セグメ		39.5%	39.4%	37.4%	38.8%	+1.4pt	-
営業利益(△:損失)	Operating income(Δ:loss)		egment from the I year	∆ 85	151	851	172	△ 678	20.3%
(売上高営業利益率)	(Ratio to Net sales)	ended Ma	arch 2018.	_	0.4%	2.3%	0.5%	-1.8pt	_
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.			8,066	8,561	8,152	8,418	266	103.3%
(売上高販促費率)	(Ratio to Net sales)			23.6%	23.8%	22.2%	23.4%	+1.2pt	_
設備投資額(有形・無形)	Capital expenditures	_	_	211	315	79	642	562	806.5%
減価償却費(有形・無形)	Depreciation and Amortization	_	_	516	516	527	540	12	102.5%

<u>宝酒造インターナショナルグループ: Takara Shuzo International Group</u> (音									
		2015年3月期 第1四半期	2016年3月期 第1四半期	2017年3月期 第1四半期	2018年3月期 第1四半期	2019年3月期 第1四半期	2020年3月期 第1四半期	前期: Change from I	*
				FY2017 (1stQ)				増減 Change	比 YOY%
売上高	Net sales	_	_	7,432	16,450	18,270	19,819	1,548	108.5%
売上原価	Cost of sales	_	_	4,989	11,683	12,721	14,259	1,538	112.1%
(売上高原価率)	(Ratio to Net sales)			67.1%	71.0%	69.6%	71.9%	+2.3pt	_
売上総利益	Gross profit	0010/50	1 #41 2 . 3 . 6	2,443	4,767	5,549	5,559	10	100.2%
販売費及び一般管理費	SG&A expenses	2018年3月 新セグメ	月期からの ントです	1,837	3,807	4,399	4,881	482	111.0%
(売上高販管費率)	(Ratio to Net sales)		egment from the	24.7%	23.1%	24.1%	24.6%	+0.6pt	_
営業利益(△:損失)	Operating income(Δ:loss)		l year arch 2018.	606	960	1,150	678	△ 471	59.0%
(売上高営業利益率)	(Ratio to Net sales)	ended ivid	arch 2010.	8.2%	5.8%	6.3%	3.4%	-2.9pt	_
のれん償却後営業利益(△:損失)	Operating income after amortization of goodwill			527	875	1,057	590	△ 467	55.8%
(のれん償却後営業利益率)	(Ratio to Net sales)	_	_	7.1%	5.3%	5.8%	3.0%	-2.8pt	_
設備投資額(有形・無形)	Capital expenditures	_	-	154	322	261	607	345	232.0%
減価償却費(有形·無形)	Depreciation and Amortization	_	_	146	230	247	292	44	118.0%
のれん償却額	Amortization of goodwill	_	_	78	85	92	87	Δ4	94.9%

タカラバイオグループ: Takara Bio Group (百万円: Millio									
		2015年3月期		2017年3月期		2019年3月期		前期 Change from I	
		第1四半期	第1四半期	第1四半期	第1四半期	第1四半期	第1四半期	増減	比
		FY2015 (1stQ)	FY2016 (1stQ)	FY2017 (1stQ)	FY2018 (1stQ)	FY2019 (1stQ)	FY2020 (1stQ)	Change	YOY%
売上高	Net sales	4,779	5,761	6,306	6,355	8,847	8,650	△ 196	97.8%
売上原価	Cost of sales	2,024	2,439	2,439	2,245	3,491	2,734	Δ 757	78.3%
(売上高原価率)	(Ratio to Net sales)	42.4%	42.3%	38.7%	35.3%	39.5%	31.6%	-7.9pt	_
売上総利益	Gross profit	2,754	3,322	3,866	4,109	5,355	5,916	560	110.5%
販売費及び一般管理費	SG&A expenses	2,689	3,210	3,223	3,846	3,811	3,664	Δ 146	96.2%
(売上高販管費率)	(Ratio to Net sales)	56.3%	55.7%	51.1%	60.5%	43.1%	42.4%	-0.7pt	_
営業利益(△:損失)	Operating income(Δ:loss)	65	111	643	262	1,544	2,251	707	145.8%
(売上高営業利益率)	(Ratio to Net sales)	1.4%	1.9%	10.2%	4.1%	17.5%	26.0%	+8.6pt	_
研究開発費	R&D expenses	703	1,020	950	1,103	1,014	939	△ 75	92.6%
(売上高研究開発費率)	(Ratio to Net sales)	14.7%	17.7%	15.1%	17.4%	11.5%	10.9%	-0.6pt	_
設備投資額(有形・無形)	Capital expenditures	782	90	211	174	678	361	∆ 317	53.2%
減価償却費(有形・無形)	Depreciation and Amortization	269	392	436	580	669	677	7	101.2%
のれん償却額	Amortization of goodwill	30	44	43	109	123	125	2	101.8%

6. 2020年3月期第1四半期 参考資料:Reference Data for the First Quarter Ended June 30, 2019

- ① 為替前提及び売上高に対する為替レート変動の影響:Exchange rates and effect of change in exchange rates on net sales
- ◆為替前提(海外子会社P/L換算用):Exchange rates for the income statement of oversea subsidiaries

(円:Yen)

	2019年3月期	2020年3月期 第1四半期					
	第1四半期	Apr. 1, 2019 -	Jun. 30, 2019				
	実績(a)	実績(b)					
	FY2019 (1stQ)	FY2020(1stQ)	前期差				
	Actual (a)	Actual (b)	Change(b-a)				
米ドル: US dollar	108.23	110.23	2.00				
ポンド: Pound	150.80	143.74	Δ 7.06				
ユーロ: Euro	133.15	125.16	△ 7.99				
人民元: Yuan	17.04	16.33	△ 0.71				
100ウォン: 100 Won	10.10	9.80	Δ 0.30				
インドルピー: Rupee	1.68	1.57	△ 0.11				
スウェーデンクローナ:Sweden krona	13.36	12.01	△ 1.35				
シンガポールドル:Singapore dollar	82.10	81.37	△ 0.73				
オーストラリアト・ル: Australian dollar	85.18	78.55	△ 6.63				

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales (百万円 :Millions of Yen)

		対前期 Change from FY2019(1stQ)
	ールディングス 計 lles of Takara Holdings IncConsolidated-	△ 414
	ち宝酒造インターナショナルグループ et sales of Takara Shuzo International Group	∆ 333
	再外酒類事業 verseas Alcoholic beverages business	Δ7
	再外日本食材卸事業 panese food wholesale business in overseas markets	△ 320
	この他 ther	_
E	直結消去 limination	Δ5
_	ちタカラバイオグループ et sales of Takara Bio Group	Δ 82
	研究用試薬 Research reagents	Δ 76
	理化学機器 Scientific instruments	Δ 0
	受託・その他 Contracted service and other	Δ5
Ві	イオ産業支援 計 ioindustry	Δ 82
	遺伝子医療 ene Therapy	_

② 海外売上高比率の推移 :Change in overseas sales ratio

					Ī)	百万円:Millions of Yen)	
	2019	年3月期第1四半期	実績	2020年3月期第1四半期 実績			
		FY2019(1stQ) Actual			FY2020(1stQ) Actual		
	売上高計	海外売上高	海外売上高比率	売上高計	海外売上高	海外売上高比率	
	Net Sales	Overseas Sales	Overseas Sales Ratio	Net Sales	Overseas Sales	Overseas Sales Ratio	
宝酒造 Takara Shuzo Co., Ltd.	36,772	_	_	36,009	_	_	
宝酒造インターナショナルグループ	18.270	18.200	99.6%	19.819	19.718	99.5%	
Takara Shuzo International Group	.0,2.0	.0,200		.0,0.0		00.070	
タカラバイオグループ Takara Bio Group	8,847	4,598	52.0%	8,650	4,713	54.5%	
その他および調整額 Other / Adjustment	3,078	_	_	2,837	_	_	
宝ホールディングス(連結) Takara Holdings IncConsolidated-	66,969	22,798	34.0%	67,317	24,432	36.3%	

PAGE 6/7 Reference Data

③ 海外主要子会社の業績:Financial Forecast of major overseas subsidiaries

					2019年3月期第1四半期 実績 FY2019(1stQ) Actual			写1四半期 実績 stQ) Actual	
						売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
米国宝酒造	千	US	k	ル	:Thousands of US dollar	7,622	919	8,576	810
Takara Sake USA Inc.	百	万		円	:Millions of Yen	824	99	945	89
宝酒造食品	千			元	:Thousands of Yuan	12,703	272	12,038	132
Takara Shuzo Foods Co.,Ltd.	百	万		円	:Millions of Yen	216	4	196	2
トマーチン	千	ポ	ン	K	:Thousands of Pound	4,142	1,258	3,723	699
The Tomatin Distillery Co.,Ltd.	百	万		円	:Millions of Yen	624	189	535	100
エイシ・インターナショナル	千	US	ĸ	ル	:Thousands of US dollar	4,578	1,914	5,591	2,486
AGE INTERNATIONAL, INC.	百	万		円	:Millions of Yen	495	207	616	274
フーデックスグループ	千	ユ	_	口	:Thousands of Euro	38,563	4,083	41,646	3,668
FOODEX Group	百	万		円	:Millions of Yen	5,134	543	5,212	459
タザキフーズ	千	ポ	ン	K	:Thousands of Pound	9,718	734	10,861	446
TAZAKI FOODS LTD.	百	万		円	:Millions of Yen	1,465	110	1,561	64
ミューチャルトレーディング	千	US	ĸ	ル	:Thousands of US dollar	79,622	3,511	89,849	1,511
Mutual Trading Co., Inc.	百	万		円	:Millions of Yen	8,617	380	9,904	166
ニッポンフード	千	AUS	ド	ル	:Thousands of Australian dollar	13,187	446	13,964	△ 893
Nippon Food Supplies Company Pty Ltd	百	万		円	:Millions of Yen	1,123	38	1,096	Δ 70
タカラハ・イオヨーロッハ。S.A.S.(連結)	千	ユ	Į	口	:Thousands of Euro	5,843	382	5,916	162
Takara Bio Europe S.A.S. Consolidated	百	万		円	:Millions of Yen	778	50	740	20
宝生物工程(大連)	千			元	:Thousands of Yuan	50,873	11,300	49,905	11,755
Takara Biotechnology (Dalian) Co.,Ltd.	百	万		円	:Millions of Yen	866	192	814	191
宝日医生物技術(北京)	千			元	:Thousands of Yuan	74,943	12,931	87,067	15,412
Takara Biomedical Technology (Beijing) Co., Ltd.	百	万		円	:Millions of Yen	1,277	220	1,421	251
タカラコリアハ゛イオメテ゛ィカル	百	万寸	ウ オ	ン	:Millions of Won	2,338	357	2,567	441
Takara Korea Biomedical Inc.	百	万		円	:Millions of Yen	236	36	251	43
タカラバイオDSSインド	千	イント゛	ルヒ	° –	:Thousands of Rupee	55,855	7,824	66,608	7,652
DSS Takara Bio India Private Limited	百	万		円	:Millions of Yen	93	13	104	12
タカラバイオUSA	千	US	ĸ	ル	:Thousands of US dollar	21,850	△ 366	23,295	1,519
Takara Bio USA, Inc.	百	万		円	:Millions of Yen	2,364	∆ 39	2,567	167

④ 宝酒造 売上総利益増減要因 :Factors of change in Gross profit of Takara Shuzo Co., Ltd.

	(百万円 :Millions of Yen)						
	対前期増減						
	Change from FY2019(1stQ)						
	増減計 数量差 単価		単価差				
	Total Change		Change in unit price				
売上総利益 計 Gross profit	△ 470	△ 329	Δ 140				
(主な内訳)							
焼酎 Shochu	△ 618	△ 595	△ 23				
清酒 Sake	△ 27	Δ9	△ 17				
ソフトアルコール飲料Light-alcohol refreshers	+250	+243	+6				
本みりん Hon Mirin	Δ 77	△ 58	△ 18				
(参考)原価コストダウン Reference :Cost reduction	Δ 89	Δ 89 ※上記数量差および単価差に *Included in changes ab					

※利益の増加要因を「+」、減少要因を「△」で表示 *An increasing factor and a decreasing factor on profit are shown 「+」 and 「△」, respectively

⑤ 宝ホールディングス(連結) 要約損益計算書 (p.1) における「その他」の内訳 Breakdown of "Other" segment in the Consolidated Statemnets of Income of Takara Holdings Inc. (Summary) (p.1)

	2019年3月期第1四半期 実績 FY2019(1stQ) Actual		2020年3月期第1四半期 実績 FY2020(1stQ) Actual	
	売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
物流事業 Transportation	3,597	172	3,507	135
宝ホールディングス(不動産事業) Takara Holdings (Real estate business)	133	110	133	111
その他 Other	4,406	225	4,041	269
「その他」計 Total "Other"	8,137	509	7,682	517